Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Application of Chitosan, Chitooligosaccharide, and Their Derivatives in the Treatment of Alzheimer's Disease.

Ouyang QQ, Zhao S, Li SD, Song C.

Mar Drugs. 2017 Nov 7;15(11). pii: E322. doi: 10.3390/md15110322. Review.

2.

Amyloidogenesis of Tau protein.

Nizynski B, Dzwolak W, Nieznanski K.

Protein Sci. 2017 Nov;26(11):2126-2150. doi: 10.1002/pro.3275. Epub 2017 Sep 13. Review.

PMID:
28833749
3.

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease.

Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, Daniele A, Greco A, Logroscino G.

Biomed Res Int. 2016;2016:3245935. doi: 10.1155/2016/3245935. Epub 2016 Jun 26. Review.

4.

Fisetin stimulates autophagic degradation of phosphorylated tau via the activation of TFEB and Nrf2 transcription factors.

Kim S, Choi KJ, Cho SJ, Yun SM, Jeon JP, Koh YH, Song J, Johnson GV, Jo C.

Sci Rep. 2016 Apr 26;6:24933. doi: 10.1038/srep24933.

5.

In Vitro Protective Effect and Antioxidant Mechanism of Resveratrol Induced by Dapsone Hydroxylamine in Human Cells.

Albuquerque RV, Malcher NS, Amado LL, Coleman MD, Dos Santos DC, Borges RS, Valente SA, Valente VC, Monteiro MC.

PLoS One. 2015 Aug 18;10(8):e0134768. doi: 10.1371/journal.pone.0134768. eCollection 2015.

6.

Mitochondrial Dysfunction Contributes to the Pathogenesis of Alzheimer's Disease.

Cabezas-Opazo FA, Vergara-Pulgar K, Pérez MJ, Jara C, Osorio-Fuentealba C, Quintanilla RA.

Oxid Med Cell Longev. 2015;2015:509654. doi: 10.1155/2015/509654. Epub 2015 Jun 29. Review.

7.

Alzheimer's disease: is a vaccine possible?

Alves RP, Yang MJ, Batista MT, Ferreira LC.

Braz J Med Biol Res. 2014 Jun;47(6):438-44. Epub 2014 Jun 3.

8.

Isoprostanes and neuroprostanes as biomarkers of oxidative stress in neurodegenerative diseases.

Miller E, Morel A, Saso L, Saluk J.

Oxid Med Cell Longev. 2014;2014:572491. doi: 10.1155/2014/572491. Epub 2014 Apr 29. Review.

9.

Tau protein modifications and interactions: their role in function and dysfunction.

Mietelska-Porowska A, Wasik U, Goras M, Filipek A, Niewiadomska G.

Int J Mol Sci. 2014 Mar 18;15(3):4671-713. doi: 10.3390/ijms15034671. Review.

10.

Are tau aggregates toxic or protective in tauopathies?

Cowan CM, Mudher A.

Front Neurol. 2013 Aug 13;4:114. doi: 10.3389/fneur.2013.00114. eCollection 2013.

11.

Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system.

Morel E, Chamoun Z, Lasiecka ZM, Chan RB, Williamson RL, Vetanovetz C, Dall'Armi C, Simoes S, Point Du Jour KS, McCabe BD, Small SA, Di Paolo G.

Nat Commun. 2013;4:2250. doi: 10.1038/ncomms3250.

12.

Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.

Ozcelik S, Fraser G, Castets P, Schaeffer V, Skachokova Z, Breu K, Clavaguera F, Sinnreich M, Kappos L, Goedert M, Tolnay M, Winkler DT.

PLoS One. 2013 May 7;8(5):e62459. doi: 10.1371/journal.pone.0062459. Print 2013.

13.

A flash in the pan: dissecting dynamic amyloid intermediates using fluorescence.

Nath A, Rhoades E.

FEBS Lett. 2013 Apr 17;587(8):1096-105. doi: 10.1016/j.febslet.2013.02.044. Epub 2013 Mar 1. Review.

14.

A powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration.

Ciaccioli G, Martins A, Rodrigues C, Vieira H, Calado P.

PLoS One. 2013;8(2):e55848. doi: 10.1371/journal.pone.0055848. Epub 2013 Feb 5.

15.

The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system.

Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT.

Am J Pathol. 2012 Oct;181(4):1426-35. doi: 10.1016/j.ajpath.2012.06.033. Epub 2012 Aug 4. Erratum in: Am J Pathol. 2012 Nov;181(5):1889-90.

16.

Structure and pathology of tau protein in Alzheimer disease.

Kolarova M, García-Sierra F, Bartos A, Ricny J, Ripova D.

Int J Alzheimers Dis. 2012;2012:731526. doi: 10.1155/2012/731526. Epub 2012 May 29.

17.

Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kövari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG.

J Neuropathol Exp Neurol. 2012 May;71(5):362-81. doi: 10.1097/NEN.0b013e31825018f7. Review.

Supplemental Content

Support Center